Managing complex projects & commercial acumen & at the heart of the deal & this is smarter healthcare for the 21st century & bringing projects to life & always delivering & that’s Healthcare with Bird & Bird
In an age where organisations are being changed by technology and the digital world, we use Bird & Bird’s expertise in IT, IP and strategic partnerships to help our clients deliver smarter healthcare for the 21st century.
Our focus on ehealth projects, strategic partnerships, outsourcings and large-scale networked IT is complemented by the ecommerce, data protection compliance and regulatory work that Bird & Bird undertakes for clients operating in the healthcare sector, as well as its medical devices work and its world-renowned life-sciences and pharmaceuticals work.
Whether you're a hospital, financial institution, government body or supplier - we have the expertise in the key technologies, processes and regulatory frameworks needed to deliver more intelligent healthcare.
Our group is based across Europe, the Middle East and Asia and has a real understanding of the sector enabling us to help you wherever you are located.
We also have exceptional insight into the challenges of delivering transformational projects and major programmes, gained through hands on support and experience. Some of our team members are also Associate Fellows at the Saïd Business School, University of Oxford where they teach on aspects of major programmes.
If you would like to know more about how we can help your business, please contact Heads of Group: Marc Martens in Brussels and Mark Hilton in London.
Chambers UK 2017
Legal 500 EMEA 2015
Chambers UK 2014
Legal 500 UK 2014
Chambers Europe 2013
Legal 500 2013
Regional Commercial Director, International US Software and Application Company
Patrick O’Connell, Chairman, Advisory Board and Practitioner Director,BT Centre for Major Programme Management, University of Oxford
Since liberalisation at the beginning of 2017, industrial and medical Cannabis have experienced a boom in Germany.
Last month, the Belgian Parliament voted in favour of a set of measures that are notably meant to clarify the regulatory landscape of the operators active in the manufacturing of Advanced Therapy Medicinal Products ...
Each Belgian biobank will have to be declared at the Federal Agency for Medicines and Health Products (FAMHP) in order to operate. It also imposes binding content for agreements on the transfer of human biological ...
There are no forthcoming events for this area. Please click on the button below to view past events.
RT @LSXLeaders: Download the brochure to see who's already coming to the LSX World Congress 2019: https://t.co/8AVOjj1jnw #LSXWORLD https:/…
RT @LifeSciencesIPR: ' A Perspective on Recent UK Supreme Court Caselaw': Chris de Mauny, Associate, Barrister, Bird & Bird takes us throug…
RT @twobirds: Supreme Court defines plausibility in the context of sufficiency - a majority postulates a new "outward presentation test" t…